This Solicitation opportunity from Department Of Health And Human Services was posted on May 4, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

One Comprehensive Universal Radiotherapy for Everyone (1-CURE)

Closed

ARPA-H-SOL-26-147Federal

Submission Closed05/23/2026, 03:59:00 AM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Grant

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)This contract opportunity from the National Institutes of Health under the Department of Health and Human Services aims to support the development of safe, effective, and non-addictive small molecule and biologic therapeutics for pain treatment. It focuses on accelerating early-stage therapeutic candidates through preclinical optimization to readiness for Phase II clinical trials. Eligible applicants must present a promising lead candidate with strong biological justification and established assays to guide optimization. The funded activities include lead optimization, early development, IND-enabling studies, biomarker development, submission of an Investigational New Drug application, and Phase I clinical testing. The program is structured as a milestone-driven, phased cooperative agreement with active NIH involvement in project planning and monitoring. The solicitation is identified as RFA-NS-27-007, titled HEAL Initiative: Non-addictive Analgesic Therapeutics Development, with clinical trials optional. The solicitation was posted on June 16, 2026, and applicants must respond by February 20, 2029. This federal contract emphasizes collaborative advancement of innovative pain therapeutics while ensuring rigorous oversight from NIH program staff throughout the project lifecycle.

National Institutes Of Health

POSTED

DEADLINE

Scientific Data Analysis & Software Tool Development for JWSTThe contract involves the development and ongoing maintenance of software tools specifically designed for the calibration of NIRISS data, pipeline processing, and support of scientific operations related to the James Webb Space Telescope (JWST). This subcontract opportunity, issued by the National Research Council of Canada under the Government of Canada, seeks expertise in scientific data analysis and software tool development to enhance JWST's data handling capabilities. The work is to be performed in British Columbia and is associated with NAICS code 541714, indicating a focus on research and development in the physical, engineering, and life sciences. The solicitation was posted on June 15, 2026, with a response deadline of June 30, 2026. Although specific details such as set-aside types, organization type, or a direct point of contact are not provided, interested parties are encouraged to refer to the official tender notice link for more information. The contract emphasizes advanced software solutions to support scientific missions, ensuring the effective processing and analysis of space telescope data crucial for ongoing research.

National Research Council of Canada

POSTED

DEADLINE

International Agricultural Research Program DesignThe contract entails the design and structuring of a comprehensive international agricultural research program that aligns with the priorities of the Foreign Agricultural Service under the Department of Agriculture. It involves developing clear objectives, detailed methodologies, and expected outcomes aimed at advancing agricultural research on a global scale. The scope emphasizes strategic planning to address international agricultural challenges while supporting USDA-FAS goals to enhance trade, sustainability, and food security. This subcontract, carrying the NAICS code 541714, was posted on June 15, 2026, with a response deadline of August 14, 2026. While specific details such as the location of performance and contact information are not provided, the focus is on crafting a program that integrates scientific research with policy priorities to foster innovation and collaboration in international agriculture. The resulting program is expected to facilitate informed decision-making and promote economic opportunities within the global agricultural sector.

Foreign Agricultural Service

POSTED

DEADLINE

TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterDC Recruiter is an innovative immune-enhancing technology developed by scientists at Los Alamos National Laboratory that uses a self-assembling peptide nanofiber to recruit and activate dendritic cells, critical components of the immune system. Unlike traditional pathogen-specific vaccines and treatments, this approach is designed to trigger an early, broad-spectrum immune response regardless of the specific infectious agent. The product is formulated as a needle-free, spray-friendly application, enhancing its practicality and ease of use in various settings. Its core advantage lies in addressing the challenge of rapid immune activation before the pathogen is identified, providing fast-acting defense during exposure scenarios where conventional methods may be delayed, too specific, or ineffective. This technology holds promise across multiple market sectors, including infectious disease prevention, outbreak management, national defense, consumer health, pharmaceuticals, and emergency preparedness. Its broad, pathogen-agnostic mechanism makes it especially valuable in high-risk or field environments requiring quick deployment and flexible administration. Currently at a technology readiness level of 3, DC Recruitor is patent-pending and available for licensing through Los Alamos National Laboratory’s program, which facilitates exclusive and non-exclusive licensing agreements to commercial partners seeking to leverage cutting-edge innovations for competitive advantage. The ongoing solicitation invites potential collaborators to engage before the stated deadline.

Triad - DOE Contractor

POSTED

DEADLINE

Contact Activation Pathway Function Blocking Antibody AB023The Defense Health Agency is conducting a Request for Information (RFI) to gather market intelligence and identify qualified sources for the supply of the contact activation pathway function blocking antibody AB023, also known as Xisomab 3G3 or Gruticibart. This antibody is designed to inhibit Coagulation Factor XI (FXI) by targeting the "apple 2" domain, preventing its activation by activated factor XII (FXIIa) in the contact pathway, which is implicated in clot formation on artificial surfaces. The antibody is intended for use in medical applications such as Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-associated thrombosis. It is designed to preserve natural clotting processes by not interfering with FXI activation by thrombin or the conversion of Factor IX by activated FXI, thus maintaining normal hemostasis required for wound healing. The Government anticipates procuring up to 0.5 grams of AB023 annually and requires pharmacokinetic and pharmacodynamic testing to assess its concentration over time, biochemical impacts, clotting time effects, and ability to prevent thrombus growth and fibrin accumulation in vascular thrombosis models. Stability, dosage, and potency validations must be conducted using clotting assays. Although this announcement does not represent a solicitation or obligation to award a contract, interested parties with relevant expertise must submit technical information by June 18, 2026. All responders must be registered in the System for Award Management (SAM). The associated NAICS code is 541714, reflecting research and development in biotechnology. The point of contact is based at the Defense Health Agency in Fort Detrick, Maryland, with the place of performance listed in Texas.

Defense Health Agency

POSTED

5 days ago

DEADLINE

in 1 day

AI Contract Overview

The contract pertains to the One Comprehensive Universal Radiotherapy for Everyone (1-CURE) program, initiated by the Advanced Research Projects Agency for Health (ARPA-H) under the Department of Health and Human Services. This solicitation, identified by ARPA-H-SOL-26-147, was posted on May 4, 2026, and invites proposals by May 23, 2026. The solicitation aims to support innovative solutions in radiotherapy, with ARPA-H anticipating multiple Other Transaction (OT) Agreements resulting from the announcement. Interested parties are encouraged to review the solicitation and its appendices, which provide detailed instructions and content requirements. The notice also directs proposers to a separate Special Notice for additional information on the Proposers’ Day event and maintains an FAQ page for ongoing updates. Several amendments have been incorporated to clarify submission requirements and documentation. Amendment 4 revises Appendix B to specify that Volume I, Element H refers to Target Product Profiles, and renames Element I to Milestone Payment Schedule with a required format. It also removes the page limit for Volume II, Cost and Pricing Data Support, and adds a new Cost Proposal Spreadsheet with Resource Sharing as Appendix L. Amendment 3 modifies Appendix F to allow certain biographical and support documentation to be submitted during the negotiation phase, rather than initially. Previously, Amendments 1 and 2 expanded the attachments by adding Appendices A through K. The contract is associated with NAICS code 541714 and is managed by the 1-CURE team based in Washington, DC.

General Info

ARPA-H invites proposals for 1-CURE radiotherapy program, multiple OT agreements expected.

Agency

Department Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Set-Aside

NONE

Documents

(17)

APPENDIX B: Full Proposal Content and Instructions for ARPA-H-SOL-26-147

DOCX•sow

Appendix K-1 CURE Gantt Chart Sample

XLSX•sow

ARPA-H-SOL-26-147 Solution Summary Content and Instructions

DOCX•sow

APPENDIX I DRAFT OTHER TRANSACTION AGREEMENT ARPA-H

DOCX•contract-document

APPENDIX B: Full Proposal Content and Instructions for ARPA-H-SOL-26-147

DOCX•sow

Appendix H: Dangerous Gain of Function Assessment for 1-CURE Proposal

DOCX•sow

Appendix J-1 Cure Cost Proposal Spreadsheet Teaming Version 1.06.02

XLSX•cost-proposal-spreadsheet

ARPA-H ISO 1-CURE Innovative Solutions Opening ARPA-H-SOL-26-147 REV1

DOCX•iso

APPENDIX C: 1-CURE Target Product Profile Guidelines

DOCX•sow

Appendix F: Administrative & National Policy Requirements Document Rev1

DOCX•sow

NIH Data Management and Sharing Plan Guidance

DOCX•sow

Appendix L-1 Cure Cost Proposal Spreadsheet Resource Sharing

XLSX•cost-proposal-spreadsheet

ARPA-H 1-CURE Solution Summary Submission Instructions

DOCX•sow

Appendix D: Task Description Document Template

DOCX•sow

Appendix F: Administrative & National Policy Requirements Document

DOCX•sow

ARPA-H SOL-26-147 1-CURE Innovative Solutions Opening

PDF•iso

APPENDIX-G-1-CURE-SECURITY-ATTESTATION-FORM.docx

DOCX

AI Contract Breakdown

Uniform Contract Format

Timeline

4 updates

PhaseClosed

Amendment 1Apr 14

Contract was updated

Amendment 2Apr 16

Contract was updated

Amendment 3Apr 29

Contract was updated

PostedMay 4

Solicitation

Amendment 4May 4

Contract was updated

Response DeadlineMay 23

Deadline has passed

Submission Closed

05/23/2026, 03:59:00 AM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)

Contacts1 person available

OfficeWashington, DC, 20005, USA

Organization / Agency

Department Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)

Office AddressWashington, DC, 20005, USA

Contacts

The 1-CURE Team

contact@example.gov

Full Description

Amendment 4: Revised Appendix B: Full Proposal Content and Instructions to consistently state that Volume I, Element H is the Target Product Profiles (TPP). Appendix B Volume I, Element I was renamed to Milestone Payment Schedule (MPS) and clarifies that the provided format in Appendix I, Attachment 3 is to be used. Appendix B Volume II Cost and Pricing Data Support page limit was removed. Appendix L: Cost Proposal Spreadsheet with Resource Sharing has been added to the attachments.

Amendment 3: Revised Appendix F: Administrative & National Policy Requirements Document, Section 3, Paragraph 1, to state that the Biographical Common Form, the Current and Pending (other) Support Common Form, and the Collaborators and Other Affiliations attachments may be provided during the negotiation phase after proposal selection.

Amendment 2: Added Appendices J & K under the Attachments section.

Amendment 1: Added Appendices A - I separately under the Attachments section.

The Advanced Research Projects Agency for Health (ARPA-H) is posting this Innovative Solutions Opening (ISO) in support of the One Comprehensive Universal Radiotherapy for Everyone (1-CURE) Program. ARPA-H anticipates that multiple Other Transaction (OT) Agreements will result from this announcement.

Interested parties are invited to review the attached 1-CURE_ISO_ARPA-H-SOL-26-147 and its Appendices A - C.

Additionally, proposers are encouraged to review the separate Special Notice, ARPA-H-SN-26-152, for information regarding the 1-CURE Proposers’ Day. Special Notice, ARPA-H-SN-26-152, is an independent announcement and is not attached to this ISO announcement.

All questions submitted to the ISO will be compiled and addressed. All answers will be posted to the 1-CURE Frequently Asked Questions (FAQ) page. Potential proposers are encouraged to monitor the FAQs page regularly for the latest information and updates: https://arpa-h.gov/explore-funding/programs/1-cure/faqs